Log in

FibroGen News Headlines (NASDAQ:FGEN)

$36.99
+2.01 (+5.75 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$35.00
Now: $36.99
$37.59
50-Day Range
$34.22
MA: $38.31
$41.62
52-Week Range
$32.33
Now: $36.99
$61.23
Volume1.00 million shs
Average Volume1.18 million shs
Market Capitalization$3.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84

Headlines

FibroGen (NASDAQ FGEN) News Headlines

Source:
DateHeadline
FibroGen Inc (NASDAQ:FGEN) Short Interest Up 5.8% in OctoberFibroGen Inc (NASDAQ:FGEN) Short Interest Up 5.8% in October
www.americanbankingnews.com - November 16 at 11:14 PM
FibroGen Inc (NASDAQ:FGEN) Expected to Announce Quarterly Sales of $50.68 MillionFibroGen Inc (NASDAQ:FGEN) Expected to Announce Quarterly Sales of $50.68 Million
www.americanbankingnews.com - November 16 at 2:52 AM
Insider Selling: FibroGen Inc (NASDAQ:FGEN) SVP Sells 5,625 Shares of StockInsider Selling: FibroGen Inc (NASDAQ:FGEN) SVP Sells 5,625 Shares of Stock
www.americanbankingnews.com - November 15 at 8:44 PM
Brokers Issue Forecasts for FibroGen Incs FY2019 Earnings (NASDAQ:FGEN)Brokers Issue Forecasts for FibroGen Inc's FY2019 Earnings (NASDAQ:FGEN)
www.americanbankingnews.com - November 15 at 11:46 AM
FY2019 EPS Estimates for FibroGen Inc (NASDAQ:FGEN) Lifted by Svb LeerinkFY2019 EPS Estimates for FibroGen Inc (NASDAQ:FGEN) Lifted by Svb Leerink
www.americanbankingnews.com - November 15 at 11:46 AM
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the FirmFIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
www.benzinga.com - November 15 at 3:52 AM
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm - Business WireFIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm - Business Wire
www.businesswire.com - November 14 at 10:51 PM
Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT - Yahoo FinanceEdited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT - Yahoo Finance
finance.yahoo.com - November 14 at 5:49 PM
Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMTEdited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT
finance.yahoo.com - November 14 at 5:49 PM
 Brokerages Anticipate FibroGen Inc (NASDAQ:FGEN) to Post -$0.39 EPS Brokerages Anticipate FibroGen Inc (NASDAQ:FGEN) to Post -$0.39 EPS
www.americanbankingnews.com - November 14 at 3:40 PM
FibroGen Inc (NASDAQ:FGEN) Expected to Post Q1 2021 Earnings of $0.46 Per ShareFibroGen Inc (NASDAQ:FGEN) Expected to Post Q1 2021 Earnings of $0.46 Per Share
www.americanbankingnews.com - November 14 at 5:07 AM
FibroGen Inc Expected to Earn Q4 2020 Earnings of $0.95 Per Share (NASDAQ:FGEN)FibroGen Inc Expected to Earn Q4 2020 Earnings of $0.95 Per Share (NASDAQ:FGEN)
www.americanbankingnews.com - November 14 at 5:02 AM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud - GlobeNewswireHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud - GlobeNewswire
www.globenewswire.com - November 14 at 12:47 AM
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors - Business WireINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors - Business Wire
www.businesswire.com - November 14 at 12:47 AM
Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors - Business WireGlancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors - Business Wire
www.businesswire.com - November 14 at 12:47 AM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities FraudHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud
finance.yahoo.com - November 14 at 12:47 AM
Svb Leerink Weighs in on FibroGen Incs Q3 2020 Earnings (NASDAQ:FGEN)Svb Leerink Weighs in on FibroGen Inc's Q3 2020 Earnings (NASDAQ:FGEN)
www.americanbankingnews.com - November 14 at 12:17 AM
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. InvestorsINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors
finance.yahoo.com - November 13 at 7:46 PM
Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. InvestorsGlancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors
finance.yahoo.com - November 13 at 7:46 PM
FibroGen (FGEN) Soars: Stock Adds 9.6% in Session - Yahoo FinanceFibroGen (FGEN) Soars: Stock Adds 9.6% in Session - Yahoo Finance
finance.yahoo.com - November 13 at 9:44 AM
FibroGen, Inc. (FGEN) CEO James Schoeneck on Q3 2019 Results - Earnings Call Transcript - Seeking AlphaFibroGen, Inc. (FGEN) CEO James Schoeneck on Q3 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 13 at 9:44 AM
Muddywaters Research links to a cautious report on FibroGen (FGEN) - StreetInsider.comMuddywaters Research links to a cautious report on FibroGen (FGEN) - StreetInsider.com
www.streetinsider.com - November 12 at 10:27 PM
FibroGen adds to selloff, down 5% on bearish Muddy Waters report - Seeking AlphaFibroGen adds to selloff, down 5% on bearish Muddy Waters report - Seeking Alpha
seekingalpha.com - November 12 at 5:27 PM
FibroGen Overcomes Safety Hurdle; Clear Path Towards FDA Approval For CKD Patients - Seeking AlphaFibroGen Overcomes Safety Hurdle; Clear Path Towards FDA Approval For CKD Patients - Seeking Alpha
seekingalpha.com - November 12 at 12:26 PM
Traders Purchase Large Volume of Put Options on FibroGen (NASDAQ:FGEN)Traders Purchase Large Volume of Put Options on FibroGen (NASDAQ:FGEN)
www.americanbankingnews.com - November 12 at 11:53 AM
FibroGen Inc Forecasted to Post FY2020 Earnings of $1.43 Per Share (NASDAQ:FGEN)FibroGen Inc Forecasted to Post FY2020 Earnings of $1.43 Per Share (NASDAQ:FGEN)
www.americanbankingnews.com - November 12 at 11:13 AM
FibroGen (NASDAQ:FGEN) Posts  Earnings Results, Beats Estimates By $0.02 EPSFibroGen (NASDAQ:FGEN) Posts Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - November 12 at 8:33 AM
FibroGen Inc (FGEN) Q3 2019 Earnings Call Transcript - The Motley FoolFibroGen Inc (FGEN) Q3 2019 Earnings Call Transcript - The Motley Fool
www.fool.com - November 12 at 7:21 AM
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo FinanceFibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
finance.yahoo.com - November 12 at 12:49 AM
FibroGen (FGEN) PT Raised to $72 at Mizuho Securities on Strong Ph3 MACE Data - StreetInsider.comFibroGen (FGEN) PT Raised to $72 at Mizuho Securities on Strong Ph3 MACE Data - StreetInsider.com
www.streetinsider.com - November 11 at 7:49 PM
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - NasdaqFibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq
www.nasdaq.com - November 11 at 7:49 PM
FibroGen Reports Third Quarter 2019 Financial Results Nasdaq:FGEN - GlobeNewswireFibroGen Reports Third Quarter 2019 Financial Results Nasdaq:FGEN - GlobeNewswire
www.globenewswire.com - November 11 at 7:49 PM
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue EstimatesFibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 11 at 7:49 PM
Here’s Why FibroGen’s Stock Popped Friday - Motley FoolHere’s Why FibroGen’s Stock Popped Friday - Motley Fool
www.fool.com - November 11 at 2:48 PM
FibroGen (FGEN) Soars: Stock Adds 9.6% in Session - NasdaqFibroGen (FGEN) Soars: Stock Adds 9.6% in Session - Nasdaq
www.nasdaq.com - November 11 at 2:48 PM
FibroGen (NASDAQ:FGEN) Given "Positive" Rating at MizuhoFibroGen (NASDAQ:FGEN) Given "Positive" Rating at Mizuho
www.americanbankingnews.com - November 11 at 9:12 AM
FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 6,000 SharesFibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 6,000 Shares
www.americanbankingnews.com - November 8 at 7:31 PM
FibroGen shares halted pending news - Seeking AlphaFibroGen shares halted pending news - Seeking Alpha
seekingalpha.com - November 8 at 6:01 PM
FibroGen up 16% as safety concerns with roxadustat ebb - Seeking AlphaFibroGen up 16% as safety concerns with roxadustat ebb - Seeking Alpha
seekingalpha.com - November 8 at 6:01 PM
FibroGen down 6% despite positive roxadustat date in late-stage CKD study - Seeking AlphaFibroGen down 6% despite positive roxadustat date in late-stage CKD study - Seeking Alpha
seekingalpha.com - November 8 at 1:00 PM
FibroGen (FGEN) Highlights Results from Ph. 3 HIMALAYAS Trial Evaluating Roxadustat for Treatment of Anemia in Incident Dialysis Patients - StreetInsider.comFibroGen (FGEN) Highlights Results from Ph. 3 HIMALAYAS Trial Evaluating Roxadustat for Treatment of Anemia in Incident Dialysis Patients - StreetInsider.com
www.streetinsider.com - November 8 at 7:59 AM
FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease - GlobeNewswireFibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease - GlobeNewswire
www.globenewswire.com - November 7 at 6:59 PM
FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney DiseaseFibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease
finance.yahoo.com - November 7 at 6:59 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN - Yahoo FinanceSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN - Yahoo Finance
finance.yahoo.com - November 6 at 4:25 PM
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of FibroGen, Inc. (FGEN) - Yahoo FinanceBronstein, Gewirtz & Grossman, LLC Announces Investigation of FibroGen, Inc. (FGEN) - Yahoo Finance
finance.yahoo.com - November 6 at 11:25 AM
Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%
finance.yahoo.com - November 6 at 11:25 AM
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of FibroGen, Inc. (FGEN)Bronstein, Gewirtz & Grossman, LLC Announces Investigation of FibroGen, Inc. (FGEN)
finance.yahoo.com - November 6 at 11:25 AM
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives SalesJazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
finance.yahoo.com - November 6 at 11:25 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN - GlobeNewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN - GlobeNewswire
www.globenewswire.com - November 5 at 10:26 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud - PRNewswireHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud - PRNewswire
www.prnewswire.com - November 5 at 10:26 PM
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: Diluted Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel